Nocturnal breathing pauses affect heart and sleep
Obstructive Sleep Apnea (OSA) is a disorder characterized by temporary cessation of breathing during sleep due to narrowing or blockage of the upper airway. This results in decreased oxygen levels and disrupted sleep, often manifesting as snoring, choking, frequent awakenings, and daytime drowsiness. Studies indicate that approximately 936 million people worldwide between the ages of 30 and 69 are affected. If left untreated, it increases the risk of cardiovascular diseases such as coronary artery disease, heart failure, and stroke. While the Continuous Positive Airway Pressure (CPAP) device remains the most effective treatment for moderate to severe cases, recent studies have shown that medications that stimulate GLP-1 receptors, like tirzepatide, can reduce the severity of the condition and improve patient outcomes—especially those linked to obesity. Results demonstrated that 42-50% of patients achieved complete remission after one year of medication use, compared to 14-16% in the placebo group. Surgical options remain a fallback when patients do not respond to medical therapy. These procedures include tissue removal, jaw position correction, or implantation of devices to stimulate the nerve, but accurate diagnosis is essential to determine the most appropriate treatment approach.
Notice: This Is an AI-Generated Summary
Comments (0)